FOCUS ON: NEUROSCIENCE AND TREATMENT THE POTENTIAL OF NEUROSCIENCE TO INFORM TREATMENT

被引:0
作者
Koob, George F. [1 ,2 ,3 ,4 ]
机构
[1] Univ Calif San Diego, Scripps Res Inst, Comm Neurobiol Addict Disorders, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Dept Psychol, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[4] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA
关键词
Alcohol and other drug dependence; alcoholism; brain; brain circuit; brain chemistry; neurotransmitters; treatment; pharmacotherapy; medications; CORTICOTROPIN-RELEASING-FACTOR; WITHDRAWAL-INDUCED ANXIETY; ETHANOL WITHDRAWAL; RECEPTOR ANTAGONISM; ALCOHOL DEPENDENCE; PROTRACTED ABSTINENCE; DRUG-ADDICTION; TOPIRAMATE; DOPAMINE; GABAPENTIN;
D O I
暂无
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
In the 40 years since the founding of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), researchers have gained a better understanding of the brain circuits and brain chemical (i.e., neurotransmitter) systems involved in the development and maintenance of alcoholism and other drug dependence. This understanding has led to the identification of numerous potential targets for pharmacotherapy of addiction. For example, insight into the roles of signaling molecules called endogenous opioids and the neurotransmitter glutamate were fundamental for developing two medications-naltrexone and acamprosate-now used in the treatment of alcoholism. However, the processes of dependence development (e.g., reinforcement, sensitization, and withdrawal) are highly complex and involve a plethora of contributing influences, which also may differ from patient to patient. Therefore, existing pharmacotherapies still are effective only for some but not all alcoholic patients. Accordingly, researchers are continuing to explore the processes involved in addiction development to identify new targets for treatment and develop new medications that can address different aspects of the dependence syndrome, thereby increasing the likelihood of successful treatment. NIAAA continues to play a pivotal role in finding and conducting this research in order to provide effective treatment options to millions of alcohol-dependent patients.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 53 条
[1]   Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study [J].
Addolorato, G ;
Caputo, F ;
Capristo, E ;
Domenicali, M ;
Bernardi, M ;
Janiri, L ;
Agabio, R ;
Colombo, G ;
Gessa, GL ;
Gasbarrini, G .
ALCOHOL AND ALCOHOLISM, 2002, 37 (05) :504-508
[2]   Rapid suppression of alcohol withdrawal syndrome by baclofen [J].
Addolorato, G ;
Caputo, F ;
Capristo, E ;
Janiri, L ;
Bernardi, M ;
Agabio, R ;
Colombo, G ;
Gessa, GL ;
Gasbarrini, G .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (03) :226-229
[3]   Dopamine partial receptor agonists reduce ethanol intake in the rat [J].
Bono, G ;
Balducci, C ;
Richelmi, P ;
Koob, GF ;
Pulvirenti, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 296 (03) :233-238
[4]   Nociceptin/orphanin FQ and drugs of abuse [J].
Ciccocioppo, R ;
Angeletti, S ;
Panocka, I ;
Massi, M .
PEPTIDES, 2000, 21 (07) :1071-1080
[5]   Baclofen suppresses motivation to consume alcohol in rats [J].
Colombo, G ;
Vacca, G ;
Serra, S ;
Brunetti, G ;
Carai, MAM ;
Gessa, GL .
PSYCHOPHARMACOLOGY, 2003, 167 (03) :221-224
[6]   Neuroprotective and abstinence-promoting effects of acamprosate - Elucidating the mechanism of action [J].
De Witte, P ;
Littleton, J ;
Parot, P ;
Koob, G .
CNS DRUGS, 2005, 19 (06) :517-537
[7]   Topiramate (topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice [J].
Farook, Justin M. ;
Morrell, Dennis J. ;
Lewis, Ben ;
Littleton, John M. ;
Barron, Susan .
ALCOHOL AND ALCOHOLISM, 2007, 42 (04) :296-300
[8]   Topiramate attenuates the stress-induced increase in alcohol consumption and preference in male C57BL/6J mice [J].
Farook, Justin M. ;
Lewis, Ben ;
Littleton, John M. ;
Barron, Susan .
PHYSIOLOGY & BEHAVIOR, 2009, 96 (01) :189-193
[9]  
FRYE GD, 1983, J PHARMACOL EXP THER, V226, P720
[10]   Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats [J].
Funk, Cindy K. ;
Zorrilla, Eric P. ;
Lee, Mei-Jing ;
Rice, Kenner C. ;
Koob, George F. .
BIOLOGICAL PSYCHIATRY, 2007, 61 (01) :78-86